Fig. 3From: A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicityHigh binding affinity of bispecific antibody AP203 to PD-L1 and CD137. A Comparison of the binding affinities of bispecific antibody AP203 and its parental antibody PD-L1 clone #6 and CD137 clone #54 to recombinant human PD-L1 (left panel) and CD137 (right panel), respectively. B Simultaneous binding of bispecific antibody AP203 to human PD-L1 and CD137 were measured by bio-layer interferometryBack to article page